Novo Nordisk A/S (ETR:NOV)
Germany · Delayed Price · Currency is EUR | Market Cap | 163.55B -21.7% |
| Revenue (ttm) | 44.06B +5.6% |
| Net Income | 15.57B +4.8% |
| EPS | 3.50 +5.0% |
| Shares Out | n/a |
| PE Ratio | 10.50 |
| Forward PE | 14.04 |
| Dividend | 1.57 (4.06%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 96,129 |
| Open | 37.64 |
| Previous Close | 38.03 |
| Day's Range | 36.87 - 37.75 |
| 52-Week Range | 30.24 - 54.87 |
| Beta | 0.34 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness
Heart disease remains humanity's top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.
Could This New Opportunity Be Worth Billions for Novo Nordisk?
A recent clinical trial win could help Novo Nordisk expand its GLP-1 addressable market. The company is looking to bounce back after multiple setbacks.
Friday's First Moves: RH & KR Earnings Mixed, NVO Downgrade
From high-end furniture to well-known grocery stores, Diane King Hall discusses what RH (RH) and Kroger (KR) earnings say about all income brackets of American consumers. As she explains, both reports...
Novo Nordisk Stock Plunges on Morgan Stanley Downgrade Warns of Semaglutide Patent Cliff
Novo Nordisk Stock Plunges on Morgan Stanley Downgrade Warns of Semaglutide Patent Cliff
Morgan Stanley Downgrades Novo Nordisk to Sell on Lilly Competition
Morgan Stanley Downgrades Novo Nordisk to Sell on Lilly Competition
Novo Nordisk Stock Falls as Morgan Stanley Doubts the Offset
Novo Nordisk Stock Falls as Morgan Stanley Doubts the Offset
Novo Nordisk Stock (NVO) Falls After Morgan Stanley’s Sell Call on Market Share Loss to Eli Lilly, Patent Cliff
Novo Nordisk shares ($NVO) fell by 2% to about $43 early Friday after Morgan Stanley Thibault Boutherin downgraded the Danish pharma giant from Hold to Sell. Boutherin said the bank’s…
Novo Nordisk downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley downgraded Novo Nordisk (NVO) to Underweight from Equal Weight with an unchanged price target of $40. The firm cites concerns over the company’s “subdued” mid-term growth and large…
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie is successfully transitioning its revenue base toward newer immunology drugs to offset the loss of patent protection for Humira. Novo Nordisk maintains a dominant position in the rapidly expand...
Novo Nordisk price target raised to DKK 320 from DKK 300 at HSBC
HSBC raised the firm’s price target on Novo Nordisk (NVO) to DKK 320 from DKK 300 and keeps a Hold rating on the shares. The firm adjusted targets in the…
Novo Nordisk says Wegovy approved in China for liver disease MASH
Denmark's Novo Nordisk said on Thursday its blockbuster weight-loss drug Wegovy had been approved in China as the first GLP-1 RA class of drugs for the treatment of metabolic dysfunction-associa...
Is Novo Nordisk AS (NVO) a Bargain After 3.1% Drop? GF Value Says Undervalued
Is Novo Nordisk AS (NVO) a Bargain After 3.1% Drop? GF Value Says Undervalued
Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?
Novo Nordisk was first to market with a GLP-1 weight-loss drug, but lost the lead to Eli Lilly. Novo Nordisk has been working hard to regain lost market share in the GLP-1 space.
Novo Nordisk (NVO) CEO Advocates for Wegovy Sales Amidst Unregulated Peptide Market
Novo Nordisk (NVO) CEO Advocates for Wegovy Sales Amidst Unregulated Peptide Market
3 of the Best Growth Stocks to Buy for Less Than $100 Right Now
Netflix, Uber, and Novo Nordisk are all excellent, undervalued stocks to buy today.
Novo Nordisk halts two trials testing ziltivekimab, Bloomberg reports
Novo Nordisk (NVO) has halted two trials testing if ziltivekimab, its experimental heart disease medicine, would help patients with heart failure, Ashleigh Furlong of Bloomberg reports. The committee ...
Novo Nordisk announces STEP Young phase 3 trial met its primary endpoint
Novo Nordisk (NVO) announced first results from the STEP Young phase 3 trial, evaluating once-weekly semaglutide in combination with a reduced-calorie diet and increased physical activity in children ...
Novo Nordisk (NVO) Hit by Another Heart Drug Setback
Novo Nordisk ($NVO) has halted two late‑stage studies of its experimental heart drug ziltivekimab, marking a major setback in its push into cardiovascular medicine. The Danish drugmaker said an indepe...
Weight-loss drug trial reports kids given ingredient in Wegovy no longer obese
Novo Nordisk said on Monday that in a late-stage trial, 40.4 per cent of children aged 6 to under 12 treated with semaglutide, the active ingredient in its blockbuster weight-loss drug Wegovy, were no...
Ozempic maker: We sold health when people wanted weight loss
Novo Nordisk invented the GLP-1 category, told the world that weight loss was the least important thing its drugs did, and then watched a competitor take market share by promising a bigger number. Mik...
Novo Nordisk Stock (NVO) Falls Despite Success in Children’s Weight-Loss Trial
Novo Nordisk’s ($NVO) shares in Copenhagen edged lower on Monday afternoon. This came even after the Danish pharma giant said in a statement that its active ingredient, semaglutide, helped to…
Novo Nordisk: STEP Young Phase 3 Trial With Semaglutide Shows Superior BMI Reduction At Week 68
(RTTNews) - Novo Nordisk (NVO, NOVOB.CO, NOV.DE) announced first results from the STEP Young phase 3 trial, evaluating once-weekly semaglutide in combination with a reduced-calorie diet and increased ...
Novo scraps two more heart drug trials, further dimming growth beyond obesity
Novo Nordisk said on Monday it had halted two additional trials of its experimental cardiovascular drug ziltivekimab, further denting the Danish drugmaker's efforts to diversify beyond its blockbust...
Novo Nordisk Says Wegovy Shot Helped Children Lose Weight in Trial
The Danish drugmaker said the clinical trial met its primary goal after 68 weeks of treatment.
Novo Nordisk says semaglutide cut obesity rates in young children in trial
Novo Nordisk said on Monday that in a late-stage trial, 40.4% of children aged 6 to under 12 treated with semaglutide, the active ingredient in its blockbuster weight-loss drug Wegovy, were...